levofloxacin

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media

Conditions

Otitis Media

Trial Timeline

Nov 1, 2002 → Jul 1, 2003

NCT ID

NCT00044473

About levofloxacin

levofloxacin is a phase 3 stage product being developed by Johnson & Johnson for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00044473. Target conditions include Otitis Media.

What happened to similar drugs?

2 of 11 similar drugs in Otitis Media were approved

Approved (2) Terminated (2) Active (7)

🔄ofloxacin otic solution 0.3%Daiichi SankyoPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccineMerckPhase 3

🔄ZmaxPfizerPhase 3

✅Saline + Fentanyl + Dexmedetomidine + DexmedetomidinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002249	Phase 1	Completed	—	—	HIV Infections
NCT00210886	Phase 3	Completed	Oct 1, 2004	Apr 1, 2006	Urinary Tract Infections
NCT00645437	Phase 1	Completed	Oct 1, 2004	Apr 1, 2006	Renal Diseases
NCT00236652	Phase 3	Completed	Nov 1, 2003	Jun 1, 2005	Maxillary Sinusitis
NCT00044473	Phase 3	Completed	Nov 1, 2002	Jul 1, 2003	Otitis Media
NCT00236522	Phase 3	Completed	Oct 1, 2002	Apr 1, 2004	Sinusitis
NCT00034736	Phase 3	Completed	Aug 1, 2002	Jun 1, 2004	Pneumonia
NCT00236821	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Pneumonia
NCT00236808	Phase 3	Completed	May 1, 2000	Nov 1, 2001	Prostatitis
NCT00249197	Phase 3	Completed	Jan 1, 1997	Jul 1, 1998	Skin Diseases, Bacterial
NCT00269932	Phase 3	Completed	Aug 1, 1993	May 1, 1994	Bronchitis, Chronic
NCT00249210	Phase 3	Completed	Aug 1, 1993	Jul 1, 1994	Sinusitis
NCT00258089	Phase 3	Completed	Jun 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00258102	Phase 3	Completed	Jan 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00257062	Phase 3	Completed	Jan 1, 1993	Apr 1, 1994	Skin Diseases, Infectious
NCT00257036	Phase 2/3	Completed	Jul 1, 1991	Feb 1, 1993	Skin Diseases, Infectious
NCT00257049	Phase 2/3	Completed	Jan 1, 1984	Jan 1, 1995	Pneumonia
NCT00257140	Phase 2/3	Completed	Jun 1, 1931	Jul 1, 1994	Bronchitis

Competing Products

15 competing products in Otitis Media

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
ofloxacin otic solution 0.3%	Daiichi Sankyo	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine	Merck	Phase 3	40
Prevenar	Pfizer	Pre-clinical	26
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
Telithromycin (HMR3647)	Sanofi	Phase 3	40
telithromycin (HMR3647)	Sanofi	Phase 3	32
Telithromycin + Azithromycin	Sanofi	Phase 3	32